Text Size

A Behavioral Trial for the Treatment of Methamphetamine Dependence. - 1

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2003 by National Institute on Drug Abuse (NIDA).
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00033124
First received: April 5, 2002
Last updated: February 8, 2007
Last verified: August 2003
History of Changes
  Purpose

The purpose of this study is to examine behavioral treatment for methamphetamine dependence.


Condition Intervention Phase
Substance-Related Disorders
 Behavioral: Behavior Therapy
 Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Behavioral Trial for the Treatment of Methamphetamine Dependence

Resource links provided by NLM:

MedlinePlus related topics: Methamphetamine
U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Withdrawal symptoms
  • New Use algorithm

Estimated Enrollment: 50
Study Start Date: July 2001
Estimated Study Completion Date: June 2002
Detailed Description:

To characterize meth. withdrawal symptoms using a multidimensional withdrawal questionnaire; to field test and investigate the effect of using an algorithm developed for discriminating between new use and residual carry-over of meth metabolites in urine and to evaluate the treatment response of meth. users to participation in the thrice weekly psychosocial protocol to be used as a "platform" in future pharmacotherapy trials.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Male or Female at least 18 yrs of age; DSM-4 diagnosis of methamphetamine (METH) dependence; be willing to comply with study procedures; verbalize understanding of consent and provide written consent and willingness to complete study procedures; be seeking treatment for METH dependence.

Exclusion Criteria:

Additional criteria available during screening at the site.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00033124

Locations
United States, California
South Bay Treatment Center
Chula Vista, California, United States, 91911
Matrix Institute on Addictions
Costa Mesa, California, United States, 92627
United States, Hawaii
John A. Burns School of Medicine
Honolulu, Hawaii, United States, 96813
United States, Iowa
Powell Chemical Dependency Center
Des Moines, Iowa, United States, 50316
United States, Missouri
Comprehensive Mental Health Services, Inc
Independence, Missouri, United States, 64052
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Richard Rawson, Ph.D. National Institute on Drug Abuse (NIDA)
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00033124     History of Changes
Obsolete Identifiers: NCT00024739
Other Study ID Numbers: NIDA-CTO-0009-1
Study First Received: April 5, 2002
Last Updated: February 8, 2007
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Substance-Related Disorders
Mental Disorders
Methamphetamine
Amphetamine
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Dopamine Agents
 Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Central Nervous System Stimulants
Central Nervous System Agents
Therapeutic Uses
Adrenergic Agents
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Dopamine Uptake Inhibitors

ClinicalTrials.gov processed this record on May 22, 2013